NCT07196579View on ClinicalTrials.gov

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Cancer
Interventions
DRUG

KXV01 TCR Lentinvivo Injection

KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reactive TCR.

Trial Locations (1)

230001

The First Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

lead

TCRx Therapeutics Co.Ltd

INDUSTRY